玻璃体注射贝伐单抗治疗眼底病的临床疗效分析

Clinical Analysis of Vitreous Injection of Bevacizumab in the Treatment of Ocular Fundus Disea

目的:探讨玻璃体注射贝伐单抗在眼底病患者治疗中的应用价值。方法:回顾性分析2015年11月至2018年10月我院收治的100例(120眼)眼底病患者病例资料,根据疾病类型将所有患者分为视网膜静脉阻塞组(RVO)、年龄相关性黄斑变性组(ARMD)、糖尿病性视网膜病变组(DR)、视网膜脉络膜新生血管组(CNV)及中心性浆液性脉络膜视网膜病变组(CSC)。所有患者均给予玻璃体注射贝伐单抗治疗,比较治疗前后患者平均眼压、最小分辨角对数(logMAR)视力,同时分析与统计临床治疗总有效率及并发症发生率。结果:治疗后各类型眼底病患者平均眼压均低于治疗前,平均logMARBCVA均高于治疗前,差异有统计学意义(P<0.05);经治疗,100例(120眼)眼底病患者中有效109眼(90.83%),无效7眼(5.83%),恶化4眼(3.33%),临床治疗总有效率为90.83%(109/120);同时有1眼(0.83%)于术后2d发生眼内炎,2眼(1.67%)发生孔源性视网膜脱离,并发症总发生率为2.50%(3/120)。结论:玻璃体注射贝伐单抗在各类型眼底病患者中治疗中均可发挥重要作用,有利于降低其眼压水平、促进视力好转,且术后并发症发生率较低,临床疗效确切。

Objective: To investigate the clinical value of vitreous injection of bevacumab in the treatment of ocular fundus disease. Methods: The data of 100 patients (120 eyes) with ocular fundus disease admitted to our hospital from November 2015 to October 2018 were retrospectively analyzed. According to the type of disease, all patients were divided into, age-related macular degeneration group (ARMD), and retinal vein occlusion group (RVO), retinal choroidal neovascularization group (CNV), diabetic retinopathy group(DR) and central serous chorioretinopathy group (CSC). All patients were treated with vitreous injection of bevacizumab. The mean intraocular pressure (IOP), minimum resolution angle logarithm (logMAR) visual acuity were compared before and after treatment, and the total effective rate and the incidence of complications were analyzed and counted. Results: After treatment, the mean intraocular pressure (IOP) of all types of ocular fundus diseases was lower than that of pre-treatment, and the mean logMARBCVA was higher than that of pre-treatment (P<0.05). After treatment, 109 eyes (90.83%) were effective, 7 eyes (5.83%) were ineffective and 4 eyes (3.33%) deteriorated in 100 cases (120 eyes) of fundus disease. The total effective rate of clinical treatment was 90.83%(109 /120). Endophthalmitis occurred in 1 eye (0.83%) 2 days after operation and rhegmatogenous retinal detachment occurred in 2 eyes (1.67%). The total incidence of complications was 2.50%(3 / 120). Conclusion: Vitreous injection of bevacumab can play an important role in the treatment of various types of ocular fundus diseases, which is helpful to reduce the level of intraocular pressure and promote the improvement of visual acuity. The incidence of postoperative complications is low, and the clinical curative effect is definite.